The Federal Government Is Taking a New Look at Psychedelic Treatments for Mental Health

National News - Mental health care in America may be on the verge of a big shift. The federal government is now pushing to speed up access to a type of treatment that was once considered off-limits - psychedelic medications.

On April 18, 2026, President Trump signed an Executive Order directing the U.S. Department of Health and Human Services to move faster on getting new treatments to people dealing with serious mental illness. That includes conditions that are hard to treat and haven't responded well to anything currently available.

Following that order, the U.S. Food and Drug Administration announced several steps it is taking to support the development of psychedelic-based medications. These are drugs that alter perception and are being studied for their potential to help people with conditions like depression, PTSD, and alcohol addiction.

Health and Human Services Secretary Robert F. Kennedy, Jr. made clear that veterans are a top priority in this effort. "Under President Trump's leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments - including psychedelic therapies like ibogaine - to confront our nation's mental health crisis head-on, especially for our veterans," he said.

FDA Commissioner Dr. Marty Makary also weighed in on why this matters. "These medications have the potential to address the nation's mental health crisis, including conditions like treatment-resistant depression, alcoholism and other serious mental health and substance abuse conditions," he said. He added that the science behind these treatments must be solid before they move forward.

So what exactly is the FDA doing? For starters, the agency is issuing special priority vouchers to three companies conducting research. One is studying psilocybin - the active ingredient in so-called "magic mushrooms" - as a treatment for hard-to-treat depression. Another is looking at psilocybin for major depressive disorder. A third is researching a drug called methylone as a potential treatment for PTSD.

The FDA is also allowing a company called DemeRx NB to begin an early-stage clinical study of a drug called noribogaine hydrochloride. This drug is a close relative of ibogaine, a powerful plant-based substance that comes from a shrub native to Africa. Ibogaine has shown early promise in helping with addiction, particularly among veterans struggling with the effects of war. This marks the first time the FDA has allowed a clinical study of an ibogaine-related drug to take place in the United States.

It's important to understand what this means - and what it doesn't. The FDA's decision to allow the study to move forward does not mean the drug has been approved. It also does not mean it has been declared safe or effective. The research will take place in a closely monitored clinical setting, and the agency will continue reviewing the data as it comes in.

The FDA is also planning to release guidance soon to help researchers design proper clinical trials for this class of drugs. Testing psychedelic medications comes with unique challenges that don't apply to more traditional drugs, and the guidance is meant to help scientists navigate those complexities the right way.

Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the FDA's Center for Drug Evaluation and Research, summed up where things stand. "There is a growing recognition of the potential of psychedelic medications to address multiple different psychiatric conditions that are notoriously difficult to treat," she said. "At the FDA we are showing our support of investigating the safety and efficacy of this class of drugs through today's actions."

For many Americans - including veterans, people living with depression, and families who have watched their loved ones struggle - this news offers a reason for cautious hope. The road from research to approved treatment is long, but the government is now signaling it is willing to explore new paths to get there.